DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  European Neuropsychopharmacology

• Publication date

  2003-05-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/S0924-977X(03)00006-3PMID 12729944
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An historical perspective on “The world-wide distribution of allele frequencies at the human dopamine D4 receptor locus”

  2014cited by this paper
• Pharmacogenetics.

  2001cited by this paper
• Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia

  2000cited by this paper
• Pharmacogenetics of schizophrenia.

  2000cited by this paper
• Pharmacogenetics. Promise and potential in child and adolescent psychiatry.

  2000cited by this paper
• Use of BPRS-A percent change scores to identify significant clinical improvement: accuracy of treatment response classification in acute psychiatric inpatients.

  1999cited by this paper
• Association of the dopamine transporter gene (DAT1) with poor methylphenidate response.

  1999cited by this paper
• Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways

  1999cited by this paper
• Child and adolescent schizophrenia.

  1998cited by this paper
• Genetic variants of dopamine receptor D4 and psychopathology.

  1998cited by this paper
• Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia.

  1998cited by this paper
• Excess dopamine D4 receptor (D4DR) exon III seven repeat allele in opioid-dependent subjects

  1997cited by this paper
• Additional evidence for an association between the dopamine D4 receptor (D4DR) exon III repeat polymorphism and the human personality trait of Novelty Seeking

  1997cited by this paper
• Psychometric properties of the K-SADS-PL in an Israeli adolescent clinical population.

  1997cited by this paper
• Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects.

  1997cited by this paper
• Population and familial association between the D4 dopamine receptor gene and measures of Novelty Seeking

  1996cited by this paper
• The association between the dopamine D4 receptor (D4DR) 16 amino acid repeat polymorphism and novelty seeking.

  1996cited by this paper
• Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking

  1996cited by this paper
• The world-wide distribution of allele frequencies at the human dopamine D4 receptor locus

  1996cited by this paper
• Association study between the dopamine D4 receptor gene and schizophrenia.

  1995cited by this paper
• Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine.

  1994cited by this paper
• Linkage analysis of schizophrenia with five dopamine receptor genes in nine pedigrees.

  1993cited by this paper
• The D4 dopamine receptor (DRD4) maps to distal 11p close to HRAS.

  1992cited by this paper
• Multiple dopamine D4 receptor variants in the human population

  1992cited by this paper
• Psychometric properties of the K-SADS-P in an Israeli adolescent inpatient population.

  1989cited by this paper
• The assessment of affective disorders in children and adolescents by semistructured interview. Test-retest reliability of the schedule for affective disorders and schizophrenia for school-age children, present episode version.

  1985cited by this paper
• Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

  1976cited by this paper
• Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs

  1976cited by this paper
• The Brief Psychiatric Rating Scale

  1962cited by this paper

• Ethnic Differences in Antipsychotic Response: What Genetic Variation Does and Does Not Tell Us

  2023cites this paper
• Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside

  2021cites this paper
• Genetic Factors Underlying Treatment Resistance in Psychiatry

  2018cites this paper
• Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability

  2018cites this paper
• Theranostic Biomarkers for Schizophrenia

  2017cites this paper
• DRD2 and DRD4 genes related to cognitive deficits in HIV-infected adults who abuse alcohol

  2015cites this paper
• The promise of biological markers for treatment response in first-episode psychosis: a systematic review.

  2015cites this paper
• EPA-1239 – Individualizing Clozapine and Risperidone Treatment For Schizophrenia Patients

  2014cites this paper
• Targeted D4 dopamine receptors: implications for drug discovery and therapeutic development.

  2013cites this paper
• Pharmacogenetics in Psychiatry

  2012cites this paper
• Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: replication and exploration.

  2012cites this paper
• Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction

  2011cites this paper
• Pharmacogenetics of Response to Antipsychotics in Patients with Schizophrenia

  2011cites this paper
• Progress in Genetic Studies of Schizophrenia

  2010cites this paper
• Pharmacogenetics of antipsychotic treatment response and side effects.

  2010cites this paper
• Review: The biological basis of antipsychotic response in schizophrenia

  2010cites this paper
• Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia.

  2010cites this paper
• Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study

  2010cites this paper
• The promise and reality of pharmacogenetics in psychiatry.

  2010cites this paper
• The promise and reality of pharmacogenetics in psychiatry.

  2010cites this paper
• Functional imaging as a tool to investigate the relationship between genetic variation and response to treatment with antipsychotics.

  2009cites this paper
• Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients.

  2009cites this paper
• DRD4 48 bp VNTR but not 5-HT2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain

  2009cites this paper
• Pharmacogenetic of response efficacy to antipsychotics in schizophrenia: pharmacodynamic aspects. Review and implications for clinical research

  2009cites this paper
• Etude des facteurs cliniques et pharmacogénétiques prédictifs de la réponse (efficacité) aux traitements neuroleptiques atypiques dans la schizophrénie

  2009cites this paper
• Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.

  2008cites this paper
• Cambridge Textbook of Effective Treatments in Psychiatry: Treatment of psychoses in children and adolescents

  2008cites this paper
• Stress, genes and the biology of suicidal behavior.

  2008cites this paper
• Pharmacogenetic study of atypical antipsychotic drug response: Involvement of the norepinephrine transporter gene

  2008cites this paper
• Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia.

  2008cites this paper
• Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients.

  2007cites this paper
• PHARMACOGENETIQUE DE LA SCHIZOPHRENIE

  2007cites this paper
• Pharmacogenetics of risperidone response and induced side effects.

  2007cites this paper
• SYCHOPHARMACOLOGIE pproche pharmacogénétique de la réponse aux ntipsychotiques chez les schizophrènes evue de la littérature harmacogenetics and treatment response in chizophrenia iterature findings

  2007cites this paper
• Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

  2007cites this paper
• Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication.

  2007cites this paper
• [Pharmacogenetics and treatment response in schizophrenia].

  2007cites this paper
• Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy.

  2007cites this paper
• The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients.

  2007cites this paper
• Pharmacogenomics: a path to predictive medicine for schizophrenia.

  2006cites this paper
• Pharmacogenetics of schizophrenia

  2006cites this paper
• Psychopharmacogenetics of schizophrenia and psychosis

  2006cites this paper
• Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.

  2005cites this paper
• Farmakogenetyka leków przeciwpsychotycznych

  2004cites this paper
• Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update.

  2004cites this paper
• Current awareness in human psychopharmacology

  2003cites this paper
• Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone

  2003cites this paper